Bain Capital Life Sciences Investors, LLC Nuvalent, Inc. Transaction History
Bain Capital Life Sciences Investors, LLC
- $557 Million
- Q3 2024
A detailed history of Bain Capital Life Sciences Investors, LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Bain Capital Life Sciences Investors, LLC holds 2,697,267 shares of NUVL stock, worth $217 Million. This represents 49.52% of its overall portfolio holdings.
Number of Shares
2,697,267
Previous 2,697,267
-0.0%
Holding current value
$217 Million
Previous $205 Million
34.85%
% of portfolio
49.52%
Previous 41.86%
Shares
3 transactions
Others Institutions Holding NUVL
# of Institutions
209Shares Held
59.5MCall Options Held
450KPut Options Held
619K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.61 Billion38.02% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5MShares$402 Million18.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.13MShares$332 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$243 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.98MShares$239 Million7.96% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.45B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...